Hormones for CNS/ Neuromusc Dis: 58.8% of denials overturned
In 17 California IMR decisions from 2016 to 2023, reviewers overturned 10 (58.8%). In the last five years: 60.0% of 5. 15 were medical-necessity disputes, 2 experimental/investigational.
By year (last five)
| Year | Decisions | Overturned |
|---|---|---|
| 2022 | 4 | 75.0% |
| 2023 | 1 | 0.0% |
What the findings mention
| What the findings mention | Decisions | Overturned | All decisions here |
|---|---|---|---|
| Published evidence citedThe findings refer to peer-reviewed or published evidence. | 6 | 66.7% | 58.8% |
| Records did not supportThe findings say the documentation did not show what was needed (usually an upheld denial). | 4 | 0.0% | 58.8% |
| Alternatives contraindicatedThe findings mention a contraindication to the plan's preferred option. | 3 | 66.7% | 58.8% |
| Prior therapies failedThe findings mention treatments that were tried without adequate response. | 3 | 66.7% | 58.8% |
Keyword matches on the reviewer’s findings, not causes. A tag that appears mostly in overturned decisions is worth documenting in an appeal; it is not a guarantee.
From recent overturned decisions
“Nature of Statutory Criteria/Case Summary: The patient has requested authorization and coverage for Cortrophin gel, five mL multidose vial (three vials for 15 day course). Ross and colleagues report that corticosteroids are currently the mainstay of treatment for relapses of MS. The authors note that adrenocorticotropic hormone (ACTH) gel, or corticotropin, is another treatment option and that reasons for using …”
“Nature of Statutory Criteria/Case Summary: The patient has requested authorization and coverage for Acthar Gel 80 units subcutaneously twice a week. The U.S. Food and Drug Administration (FDA) approves the use of Acthar Gel for the indication of nephrotic syndrome. Medical literatures report that Acthar Gel may meet an important treatment need in patients with treatment-resistant nephrotic syndrome in response …”
“Nature of Statutory Criteria/Case Summary: The patient has requested authorization and coverage for Acthar Gel. High-dose corticosteroid therapy is the mainstay of treatment for acute exacerbations of multiple sclerosis (MS). Findings: The physician reviewer found that the U.S. Food and Drug Administration (FDA) approves the use of Acthar Gel, an adrenocorticotropic hormone (ACTH), for the treatment of exacerbations of multiple …”
And one the reviewer upheld
“Nature of Statutory Criteria/Case Summary: The patient’s parent has requested reimbursement and prospective authorization and coverage for the requested Emflaza 6 mg tablets (two tablets in the morning – 10 days on and 10 days off regimen).Findings: The physician reviewer found that the current medical records, this patient presents with a history of Duchenne muscular dystrophy. The patient’s provider has …”
- California only: these are decisions by independent reviewers under California's IMR program (plans regulated by the Department of Managed Health Care). Other states and self-funded employer plans use different reviewers and rules.
- Selection: only denials that a member took all the way to IMR appear. Most denials are never appealed, and the ones that reach an external reviewer are not a random sample.
- Overturned means the reviewer disagreed with the plan; it does not mean the treatment worked or that a similar request will be approved.
- Argument tags are keyword matches on the reviewer's findings. They describe what the findings mention, not why the case was decided.
- Categories are DMHC's own labels (treatment sub-category and diagnosis category); 'Other' is a catch-all and is excluded from rankings.
Source: California Department of Managed Health Care, Independent Medical Review (IMR) Determinations, Trend (CHHS Open Data). Public California government data; Apellica's aggregates and tags are CC BY 4.0.
Questions
How often were Hormones denials for CNS/ Neuromusc Dis overturned?
In 17 California IMR decisions from 2016 to 2023, reviewers overturned 10 (58.8%). In the last five years: 60.0% of 5. 15 were medical-necessity disputes, 2 experimental/investigational.
What should an appeal document, based on these findings?
Whatever the plan's criteria ask for, shown in the record: the treatments already tried and their results, contraindications to the plan's preferred option, the guideline or evidence that supports the request, and the treating clinician's reasoning written to the criteria. The tag table shows which of these the reviewers mentioned most in overturned cases.
Does a California IMR result apply to my plan?
Only California plans regulated by the Department of Managed Health Care go to IMR. Other states and self-funded employer plans use different reviewers, but they weigh the same things.
Independent reviewers reverse plans when the record answers the criteria. Upload the denial letter; a senior reviewer reads it within 24 hours and tells you in writing whether it can be appealed and how. $0 upfront, 10% of what is recovered, nothing if we do not recover. Not a law firm.